Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/73862
Título
A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
Autor
Año del Documento
2020
Editorial
American Chemical Society
Descripción
Producción Científica
Documento Fuente
Molecular Pharmaceutics, 2020, vol. 17, n. 5, p. 1608-1620
Resumen
This work analyzes the immunogenicity of six genetically engineered constructs based on elastin-like recombinamers (ELRs) fused to the Gn glycoprotein from Rift Valley fever virus (RVFV). Upon transfection, all constructs showed no effect on cell viability. While fusion constructs including ELR blocks containing hydrophobic amino acids (alanine or isoleucine) did not increase the expression of viral Gn in eukaryotic cells, glutamic acid- or valine-rich fusion proteins showed enhanced expression levels compared with the constructs encoding the viral antigen alone. However, in vivo DNA plasmid immunization assays determined that the more hydrophobic constructs reduced viremia levels after RVFV challenge to a higher extent than glutamic- or valine-rich encoding plasmids and were better inducers of cellular immunity as judged by in vitro restimulation experiments. Although the Gn-ELR fusion constructs did not surpass the protective efficacy of a plasmid vaccine expressing nonfused Gn, our results warrant further experiments directed to take advantage of the immunomodulatory potential of ELR biomaterials for improving vaccines against infectious diseases.
Palabras Clave
Rift Valley fever virus
DNA vaccines
elastin-like recombinamers (ELRs)
vaccine technologies
in vivo immunogenicity
ISSN
1543-8384
Revisión por pares
SI
Patrocinador
Unión Europea-Horizonte 2020 (H2020-NMP-2014-64607)
Ministerio de Ciencia, Innovación y Universidades (DTS19/00162,MAT2016-79435-R, MAT2016-78903-R, AGL2017-82336-R)
Comunidad de Madrid (2018/BAA-4370)
Junta de Castilla y León (VA317P18)
CIBER-BBN
Centro en Red de Medicina regenerativa y Terapia celular de Castilla y León
Ministerio de Ciencia, Innovación y Universidades (DTS19/00162,MAT2016-79435-R, MAT2016-78903-R, AGL2017-82336-R)
Comunidad de Madrid (2018/BAA-4370)
Junta de Castilla y León (VA317P18)
CIBER-BBN
Centro en Red de Medicina regenerativa y Terapia celular de Castilla y León
Version del Editor
Propietario de los Derechos
© 2020 American Chemical Society
Idioma
eng
Tipo de versión
info:eu-repo/semantics/submittedVersion
Derechos
openAccess
Aparece en las colecciones
Ficheros en el ítem
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional